In this video, Daniel Wolff, MD, PhD, University Hospital of Regensburg, Regensburg, Germany, outlines the advantages and limitations of ruxolitinib for the treatment of chronic graft-versus-host disease (cGvHD). Recently, the Phase III REACH3 trial (NCT03112603) showed that ruxolitinib was superior to best available therapy in patients with steroid-refractory cGvHD. This evidence has put into question whether ruxolitinib should be the new standard of care for second-line treatment of cGvHD. Whilst ruxolitinib was proven to be highly efficacious in the REACH3 trial, approximately 40% of patients did not benefit, and patient characteristics which may allow the identification of patients who will respond to ruxolitinib are currently unknown. In addition, ruxolitinib is associated with side effects such as uncontrolled infections. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
